Overview

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

Status:
COMPLETED

Trial end date:
2024-09-17

Target enrollment:

Participant gender:

Summary

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

Phase:

PHASE1

Details

Lead Sponsor:

Acumen Pharmaceuticals